Vnitr Lek 2015, 61(7-8):635-640

Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide

Martin Haluzík*, Pavel Trachta, Miloš Mráz
III. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

Cardiovascular risk reduction is the major aim of type 2 diabetes mellitus treatment. The effects of various antidiabetics on the cardiovascular complications are currently under careful scrutiny. Incretin-based therapy that utilizes the effects of glucagon-like peptide 1 (GLP-1) or stimulation of its receptor by GLP-1 receptor agonists represents one of the most promising approaches from the potential cardiovascular risk reduction point of view. Experimental studies have shown that the GLP-1 and GLP-1 agonists treatment improves endothelial function, decrease blood pressure and protects myocardium during experimentally-induced ischemia. Clinical studies with GLP-1 receptor agonists consistently show that, in addition to good antidiabetic efficacy, its long-term administration decreases blood pressure, body weight and improves circulating lipid levels while slightly increasing heart rate. In this paper, we focus on the cardiovascular effects of GLP-1 receptor agonist liraglutide. Preliminary analyses of cardiovascular complications in phase III trials with liraglutide indicate its good cardiovascular safety. A possibility of cardioprotective effects of liraglutide remains still open and is currently studied within a prospective cardiovascular trial LEADER.

Keywords: cardiovascular complications; diabetes mellitus; GLP-1 agonists; glucagon-like peptide 1; liraglutide

Received: January 23, 2015; Accepted: March 16, 2015; Published: July 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Haluzík M, Trachta P, Mráz M. Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide. Vnitr Lek. 2015;61(7-8):635-640.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. O'Rahilly. S Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. BMJ 1997; 314 (7085): 955-959. Go to original source... Go to PubMed...
    2. Škrha J. Diabetes mellitus 2002 v České republice - epidemiologická studie. DMEV 2005; 8(1): 5-12.
    3. Banegas JR, Lopez-Garcia E, Gutierrez-Fisac JL et al. A simple estimate of mortality attributable to excess weight in the European Union. Eur J Clin Nutr 2003; 57(2): 201-208. Go to original source... Go to PubMed...
    4. Bell D. Pathophysiology of type 2 diabetes and its relationship to new therapeutic approaches. Diabetes Educ 2000; 26(Suppl): S4-S7.
    5. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance, and cardiovascular disease. Recent Prog Horm Res 2004; 59: 207-223. Go to original source... Go to PubMed...
    6. Svačina S, Owen K. Syndrom inzulínové rezistence. Triton: Praha 2003. ISBN 80-7254-353-9.
    7. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339(4): 229-234. Go to original source... Go to PubMed...
    8. Škrha J et al. Diabetologie. Galén: Praha 2009. ISBN 978-80-7262-607-6.
    9. de Galan BE, Zoungas S, Chalmers J et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia 2009; 52(11): 2328-2336. Go to original source... Go to PubMed...
    10. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355(23): 2427-2443. Go to original source... Go to PubMed...
    11. Ahren B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 2009; 23(4): 487-498. Go to original source... Go to PubMed...
    12. Deacon CF, Mannucci E, Ahren B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab 2012; 14(8): 762-767. Go to original source... Go to PubMed...
    13. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab.2004; 287(2): E199-E206. Go to original source... Go to PubMed...
    14. Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Re. 2004; 36(11-12): 852-858. Go to original source... Go to PubMed...
    15. Gleeson JM, Berenbeim DM, Gilkin RJ. Incretin mimetics: promising new therapeutic options in the treatment of type 2 diabetes. J Manag Care Pharm 2005; 11(Suppl 7): S2-S13. Go to original source... Go to PubMed...
    16. Doggrell SA Is liraglutide or exenatide better in type 2 diabetes? Expert Opin Pharmacother 2009; 10(16): 2769-2772. Go to PubMed...
    17. Roubíček T, Mráz M, Bártlová M et al. Vliv 6měsíčního podávání exenatidu na kompenzaci diabetes mellitus 2. typu, antropometrické a biochemické parametry. Vnitř Lék 2010; 56(1): 15-20. Go to PubMed...
    18. Haluzík M, Svačina Š. Inkretinová léčba diabetu. Mladá Fronta: Praha 2010. ISBN 978-80-204-2247-7.
    19. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3(3): 153-165. Go to original source... Go to PubMed...
    20. Ban K, Noyan-Ashraf MH, Hoefer J et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117(18): 2340-2350. Go to original source... Go to PubMed...
    21. Abu-Hamdah R, Rabiee A, Meneilly GS et al. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009; 94(6): 1843-1852. Go to original source... Go to PubMed...
    22. Nikolaidis LA, Elahi D, Hentosz T et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110(8): 955-961. Go to original source... Go to PubMed...
    23. Timmers L, Henriques JP, de Kleijn DP et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009; 53(6): 501-510. Go to original source... Go to PubMed...
    24. Noyan-Ashraf MH, Momen MA, Ban K et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009; 58(4): 975-983. Go to original source... Go to PubMed...
    25. Sokos GG, Nikolaidis LA, Mankad S et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006; 12(9): 694-699. Go to original source... Go to PubMed...
    26. Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109(8): 962-965. Go to original source... Go to PubMed...
    27. Sokos GG, Bolukoglu H, German J et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007; 100(5): 824-829. Go to original source... Go to PubMed...
    28. Davidson MH. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol 2011; 108(Suppl 3): S33B-S41B. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2011.03.046>. Go to original source... Go to PubMed...
    29. Koska J, Schwartz EA, Mullin MP et al. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care 2010; 33(5): 1028-1030. Go to original source... Go to PubMed...
    30. Pyke C, Heller RS, Kirk RK et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014; 155(4): 1280-1290. Go to original source... Go to PubMed...
    31. Davies MJ, Kela R, Khunti K. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab 2011; 13(3): 207-220. Go to original source... Go to PubMed...
    32. Drucker DJ, Dritselis A, Kirkpatrick P. Liraglutide. Nat Rev Drug Discov 2010; 9(4): 267-268. Go to original source... Go to PubMed...
    33. Sturis J, Gotfredsen CF, Romer J et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003; 140(1): 123-132. Go to original source... Go to PubMed...
    34. Kristensen J, Mortensen UM, Schmidt M et al. Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC cardiovascular disorders 2009; 9: 31. Dostupné z DOI: <http://dx.doi.org/10.1186/1471-2261-9-31>. Go to original source... Go to PubMed...
    35. Ahren B. GLP-1 and extra-islet effects. Horm Metab Res 2004; 36(11-12): 842-845. Go to original source... Go to PubMed...
    36. Hegedus L, Moses AC, Zdravkovic M et al. GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide. J Clin Endocrinol Metab 2011; 96(3): 853-860. Go to original source... Go to PubMed...
    37. Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32(7): 1224-1230. Go to original source... Go to PubMed...
    38. Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther 2009; 31(11): 2472-2488. Go to original source... Go to PubMed...
    39. Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374(9683): 39-47. Go to original source... Go to PubMed...
    40. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373(9662): 473-481. Go to original source... Go to PubMed...
    41. Marre M, Shaw J, Brandle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26(3): 268-278. Go to original source... Go to PubMed...
    42. Vilsboll T, Zdravkovic M, Le-Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30(6): 1608-1610. Go to original source... Go to PubMed...
    43. Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52(10): 2046-2055. Go to original source... Go to PubMed...
    44. Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32(1): 84-90. Go to original source... Go to PubMed...
    45. Pratley RE, Nauck M, Bailey T et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375(9724): 1447-1456. Go to original source... Go to PubMed...
    46. Robinson LE, Holt TA, Rees K et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ open 2013; 3(1). Dostupné z DOI: <http://dx.doi.org/10.1136/bmjopen-2012-001986>. Go to original source... Go to PubMed...
    47. Hermansen K, Baekdal TA, During M et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab 2013; 15(11): 1040-1048. Go to original source... Go to PubMed...
    48. Marso SP, Poulter NR, Nissen SE et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 2013; 166(5): 823-830e5. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2013.07.012>. Go to original source... Go to PubMed...
    49. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317-1326. Go to original source... Go to PubMed...
    50. White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369(14): 1327-1235. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.